Chemoreflex Sensitivity in Chronic Kidney Disease
Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease
1 other identifier
observational
65
1 country
1
Brief Summary
Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 CKD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2008
CompletedFirst Submitted
Initial submission to the registry
November 19, 2008
CompletedFirst Posted
Study publicly available on registry
November 20, 2008
CompletedNovember 20, 2008
November 1, 2008
1.8 years
November 19, 2008
November 19, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease
Study Arms (3)
1
Patients with stage 3 CKD
2
Patients with stage 4 CKD
3
Patients without evidence for CDK
Interventions
Eligibility Criteria
You may qualify if:
- Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
- For the reference Patients without evidence for CDK
You may not qualify if:
- Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RWTH Aachen Universitylead
- Heinrich-Heine University, Duesseldorfcollaborator
- SLK Kliniken Heilbronn GmbHcollaborator
Study Sites (1)
Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine
Aachen, North Rhine-Westphalia, 52074, Germany
Biospecimen
Measurement of the venous partial pressure of oxygen in blood samples
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christian Meyer, MD
RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 19, 2008
First Posted
November 20, 2008
Study Start
January 1, 2007
Primary Completion
November 1, 2008
Study Completion
November 1, 2008
Last Updated
November 20, 2008
Record last verified: 2008-11